VIveve Patents a New Method of Stress Urinary Incontinence Treatment in Australia.
- ByManjeet Singh | September 27, 2021
Viveve Medical, Inc. is a medical technology company focused on women’s intimate health that has received clearance from the Food and Drug Administration (FDA) to use in general surgical procedures for electrocoagulation and hemostasis. It was announced on September 22 that the United States Patent and Trademark Office (USPTO) had issued US Patent 107779874, which covers Viveve’s method to cure stress urinary incontinence (SUI). As a result of the newly granted patent, Pursuit is strengthening its IP portfolio as it prepares to launch its pivotal PURSUIT trial in the U.S. for the treatment of female SUI.
“We are pleased with the issuance of the SUI patent in Australia. The addition of this new patent strengthens the Company’s already robust intellectual property portfolio, recently expanded by a U.S. and two Asia Pacific patents and a U.S. SUI patent issued in the fall of 2020. As we continue to advance our pivotal PURSUIT trial, our strong IP position supports Viveve’s focus to develop and commercialize a new method for the treatment of SUI pending regulatory approval,” said Scott Durbin, Viveve’s chief executive officer.
“Currently, there is an enormous unmet need in the market for a non-invasive, safe, efficacious, and durable SUI treatment. We look forward to completing enrollment in our PURSUIT clinical trial early in the fourth quarter of this year. Positive results from this trial may support a new U.S. indication for the treatment of moderate SUI in women,” concluded Mr. Durbin.
Follow Startup Story
Related Posts
